MicroRNA-210 and its theranostic potential

References

• Peng WJ, Tao JH, Mei B, et al. MicroRNA-29: a potential therapeutic target for systemic sclerosis. Expert Opin Ther Targets. 2012;16(9):875–879.
   PubMed Web of Science ®Google Scholar
• Chen X, Liang H, Zhang J, et al. Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol. 2012;22(3):125–132.
   PubMed Web of Science ®Google Scholar
• Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–659.
   PubMed Web of Science ®Google Scholar
• Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011;13(4):423–433.
   PubMed Web of Science ®Google Scholar
• Gregory RI, Chendrimada TP, Cooch N, et al. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell. 2005;123(4):631–640.
   PubMed Web of Science ®Google Scholar
• Lujambio A, Lowe SW. The microcosmos of cancer. Nature. 2012;482(7385):347–355.
   PubMed Web of Science ®Google Scholar
• Da Sacco L, Masotti A. Recent insights and Novel bioinformatics tools to understand the role of MicroRNAs binding to 5ʹ untranslated region. Int J Mol Sci. 2012;14(1):480–495.
   PubMed Web of Science ®Google Scholar
• Huang S, Wu S, Ding J, et al. MicroRNA-181a modulates gene expression of zinc finger family members by directly targeting their coding regions. Nucleic Acids Res. 2010;38(20):7211–7218.
   PubMed Web of Science ®Google Scholar
• Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science. 2007;318(5858):1931–1934.
   PubMed Web of Science ®Google Scholar
• Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433(7027):769–773.
   PubMed Web of Science ®Google Scholar
• Chan SY, Loscalzo J. MicroRNA-210: a unique and pleiotropic hypoxamir. Cell Cycle. 2010;9(6):1072–1083.
   PubMed Web of Science ®Google Scholar
• Huang X, Ding L, Kl B, et al. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell. 2009;35(6):856–867.
   PubMed Web of Science ®Google Scholar
• Greither T, Grochola LF, Udelnow A, et al. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer. 2010;126(1):73–80.
   PubMed Web of Science ®Google Scholar
• Camps C, Buffa FM, Colella S, et al. hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res. 2008;14(5):1340–1348.
   PubMed Web of Science ®Google Scholar
• Huang X, Le QT, Giaccia AJ. MiR-210–micromanager of the hypoxia pathway. Trends Mol Med. 2010;16(5):230–237.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Li L, Tan X, et al. miR-210 mediates vagus nerve stimulation-induced antioxidant stress and anti-apoptosis reactions following cerebral ischemia/reperfusion injury in rats. J Neurochem. 2015;134(1):173–181.
   PubMed Web of Science ®Google Scholar
• Chan YC, Banerjee J, Choi SY, et al. miR-210: the master hypoxamir. Microcirculation. 2012;19(3):215–223.
   PubMed Web of Science ®Google Scholar
• Noman MZ, Buart S, Romero P, et al. Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res. 2012;72(18):4629–4641.
   PubMed Web of Science ®Google Scholar
• Chen Z, Li Y, Zhang H, et al. Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression. Oncogene. 2010;29(30):4362–4368.
   PubMed Web of Science ®Google Scholar
• Faraonio R, Salerno P, Passaro F, et al. A set of miRNAs participates in the cellular senescence program in human diploid fibroblasts. Cell Death Differ. 2012;19(4):713–721.
   PubMed Web of Science ®Google Scholar
• Kushibiki T. Photodynamic therapy induces microRNA-210 and −296 expression in HeLa cells. J Biophotonics. 2010;3(5–6):368–372.
   PubMed Web of Science ®Google Scholar
• Fasanaro P, D’Alessandra Y, Di Stefano V, et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem. 2008;283(23):15878–15883.
   PubMed Web of Science ®Google Scholar
• Hale A, Lee C, Annis S, et al. An Argonaute 2 switch regulates circulating miR-210 to coordinate hypoxic adaptation across cells. Biochim Biophys Acta. 2014;1843(11):2528–2542.
   PubMed Web of Science ®Google Scholar
• Fasanaro P, Romani S, Voellenkle C, et al. ROD1 is a seedless target gene of hypoxia-induced miR-210. PLoS One. 2012;7(9):e44651.
   PubMed Web of Science ®Google Scholar
• Magenta A, Greco S, Gaetano C, et al. Oxidative stress and microRNAs in vascular diseases. Int J Mol Sci. 2013;14(9):17319–17346.
   PubMed Web of Science ®Google Scholar
• Nakada C, Tsukamoto Y, Matsuura K, et al. Overexpression of miR-210, a downstream target of HIF1alpha, causes centrosome amplification in renal carcinoma cells. J Pathol. 2011;224(2):280–288.
   PubMed Web of Science ®Google Scholar
• Biswas S, Roy S, Banerjee J, et al. Hypoxia inducible microRNA 210 attenuates keratinocyte proliferation and impairs closure in a murine model of ischemic wounds. Proc Natl Acad Sci USA. 2010;107(15):6976–6981.
   PubMed Web of Science ®Google Scholar
• Wang H, Bian S, Yang CS. Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1alpha. Carcinogenesis. 2011;32(12):1881–1889.
   PubMed Web of Science ®Google Scholar
• Hu S, Huang M, Li Z, et al. MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation. 2010;122(11 Suppl):S124–S131.
   PubMed Web of Science ®Google Scholar
• McCormick RI, Blick C, Ragoussis J, et al. miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. Br J Cancer. 2013;108(5):1133–1142.
   PubMed Web of Science ®Google Scholar
• Yang H, Li TW, Peng J, et al. A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression. Gastroenterology. 2011;141(1):378–388, 388 e1–4.
   Web of Science ®Google Scholar
• Puissegur MP, Mazure NM, Bertero T, et al. miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ. 2011;18(3):465–478.
   PubMed Web of Science ®Google Scholar
• Kulshreshtha R, Davuluri RV, Calin GA, et al. A microRNA component of the hypoxic response. Cell Death Differ. 2008;15(4):667–671.
   PubMed Web of Science ®Google Scholar
• Mok Y, Schwierzeck V, Thomas DC, et al. MiR-210 is induced by Oct-2, regulates B cells, and inhibits autoantibody production. J Immunol. 2013;191(6):3037–3048.
   PubMed Web of Science ®Google Scholar
• Mutharasan RK, Nagpal V, Ichikawa Y, et al. microRNA-210 is upregulated in hypoxic cardiomyocytes through Akt- and p53-dependent pathways and exerts cytoprotective effects. Am J Physiol Heart Circ Physiol. 2011;301(4):H1519–H1530.
   PubMed Web of Science ®Google Scholar
• Greco S, Gaetano C, Martelli F. HypoxamiR regulation and function in ischemic cardiovascular diseases. Antioxid Redox Signal. 2014;21(8):1202–1219.
   PubMed Web of Science ®Google Scholar
• Muralimanoharan S, Guo C, Myatt L, et al. Sexual dimorphism in miR-210 expression and mitochondrial dysfunction in the placenta with maternal obesity. Int J Obes (Lond). 2015;39(8):1274–1281.
   PubMed Web of Science ®Google Scholar
• Liu SC, Chuang SM, Hsu CJ, et al. CTGF increases vascular endothelial growth factor-dependent angiogenesis in human synovial fibroblasts by increasing miR-210 expression. Cell Death Dis. 2014;5:e1485.
   PubMed Web of Science ®Google Scholar
• Chapoval S, Dasgupta P, Dorsey NJ, et al. Regulation of the T helper cell type 2 (Th2)/T regulatory cell (Treg) balance by IL-4 and STAT6. J Leukoc Biol. 2010;87(6):1011–1018.
   PubMed Web of Science ®Google Scholar
• Cui H, Seubert B, Stahl E, et al. Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes. Oncogene. 2015;34(28):3640–3650.
   PubMed Web of Science ®Google Scholar
• Kim JH, Park SG, Song SY, et al. Reactive oxygen species-responsive miR-210 regulates proliferation and migration of adipose-derived stem cells via PTPN2. Cell Death Dis. 2013;4:e588.
   PubMed Web of Science ®Google Scholar
• Xiong L, Wang F, Huang X, et al. DNA demethylation regulates the expression of miR-210 in neural progenitor cells subjected to hypoxia. FEBS J. 2012;279(23):4318–4326.
   PubMed Web of Science ®Google Scholar
• Bye A, Rosjo H, Aspenes ST, et al. Circulating microRNAs and aerobic fitness–the HUNT-Study. PLoS One. 2013;8(2):e57496.
   PubMed Web of Science ®Google Scholar
• Merlo A, de Quiros SB, de Santa-Maria IS, et al. Identification of somatic VHL gene mutations in sporadic head and neck paragangliomas in association with activation of the HIF-1alpha/miR-210 signaling pathway. J Clin Endocrinol Metab. 2013;98(10):E1661–E1666.
   PubMed Web of Science ®Google Scholar
• Tsang VH, Dwight T, Benn DE, et al. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours. Endocr Relat Cancer. 2014;21(3):415–426.
   PubMed Web of Science ®Google Scholar
• Selbach M, Schwanhausser B, Thierfelder N, et al. Widespread changes in protein synthesis induced by microRNAs. Nature. 2008;455(7209):58–63.
   PubMed Web of Science ®Google Scholar
• Tsuchiya S, Fujiwara T, Sato F, et al. MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J Biol Chem. 2011;286(1):420–428.
   PubMed Web of Science ®Google Scholar
• Giannakakis A, Sandaltzopoulos R, Greshock J, et al. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther. 2008;7(2):255–264.
   PubMed Web of Science ®Google Scholar
• He J, Wu J, Xu N, et al. MiR-210 disturbs mitotic progression through regulating a group of mitosis-related genes. Nucleic Acids Res. 2013;41(1):498–508.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhu T, Chen Y, et al. Human growth hormone-regulated HOXA1 is a human mammary epithelial oncogene. J Biol Chem. 2003;278(9):7580–7590.
   PubMed Web of Science ®Google Scholar
• Zhang GL, Li YX, Zheng SQ, et al. Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210. Antiviral Res. 2010;88(2):169–175.
   PubMed Web of Science ®Google Scholar
• Kiga K, Mimuro H, Suzuki M, et al. Epigenetic silencing of miR-210 increases the proliferation of gastric epithelium during chronic Helicobacter pylori infection. Nat Commun. 2014;5:4497.
   PubMed Web of Science ®Google Scholar
• Harris AL. Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2(1):38–47.
   PubMed Web of Science ®Google Scholar
• Yoshioka Y, Kosaka N, Ochiya T, et al. Micromanaging iron Homeostasis: hypoxia-inducible micro-RNA-210 suppresses iron homeostasis-related proteins. J Biol Chem. 2012;287(41):34110–34119.
   PubMed Web of Science ®Google Scholar
• Okamoto M, Nasu K, Abe W, et al. Enhanced miR-210 expression promotes the pathogenesis of endometriosis through activation of signal transducer and activator of transcription 3. Hum Reprod. 2015;30(3):632–641.
   PubMed Web of Science ®Google Scholar
• Li L, Huang K, You Y, et al. Hypoxia-induced miR-210 in epithelial ovarian cancer enhances cancer cell viability via promoting proliferation and inhibiting apoptosis. Int J Oncol. 2014;44(6):2111–2120.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Challapalli A, Smith G, et al. Imaging apoptosis with positron emission tomography: ‘bench to bedside’ development of the caspase-3/7 specific radiotracer [(18)F]ICMT-11. Eur J Cancer. 2012;48(4):432–440.
   PubMed Web of Science ®Google Scholar
• Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 2008;9(3):231–241.
   PubMed Web of Science ®Google Scholar
• Cheng AM, Byrom MW, Shelton J, et al. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005;33(4):1290–1297.
   PubMed Web of Science ®Google Scholar
• Lee DW, Futami M, Carroll M, et al. Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155. Oncogene. 2012;31(37):4085–4094.
   PubMed Web of Science ®Google Scholar
• Wang F, Xiong L, Huang X, et al. miR-210 suppresses BNIP3 to protect against the apoptosis of neural progenitor cells. Stem Cell Res. 2013;11(1):657–667.
   PubMed Web of Science ®Google Scholar
• Gou D, Ramchandran R, Peng X, et al. miR-210 has an antiapoptotic effect in pulmonary artery smooth muscle cells during hypoxia. Am J Physiol Lung Cell Mol Physiol. 2012;303(8):L682–L691.
   PubMed Web of Science ®Google Scholar
• Yang W, Sun T, Cao J, et al. Downregulation of miR-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells in vitro. Exp Cell Res. 2012;318(8):944–954.
   PubMed Web of Science ®Google Scholar
• Chio CC, Lin JW, Cheng HA, et al. MicroRNA-210 targets antiapoptotic Bcl-2 expression and mediates hypoxia-induced apoptosis of neuroblastoma cells. Arch Toxicol. 2013;87(3):459–468.
   PubMed Web of Science ®Google Scholar
• Chan SY, Zhang YY, Hemann C, et al. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab. 2009;10(4):273–284.
   PubMed Web of Science ®Google Scholar
• Link JM, Ota S, Zhou ZQ, et al. A critical role for Mnt in Myc-driven T-cell proliferation and oncogenesis. Proc Natl Acad Sci USA. 2012;109(48):19685–19690.
   PubMed Web of Science ®Google Scholar
• Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011;146(6):873–887.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298–307.
   PubMed Web of Science ®Google Scholar
• Suarez Y, Fernandez-Hernando C, Yu J, et al. Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc Natl Acad Sci USA. 2008;105(37):14082–14087.
   PubMed Web of Science ®Google Scholar
• Foekens JA, Sieuwerts AM, Smid M, et al. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci USA. 2008;105(35):13021–13026.
   PubMed Web of Science ®Google Scholar
• Kosaka N, Iguchi H, Hagiwara K, et al. Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal transfer of angiogenic microRNAs regulate cancer cell metastasis. J Biol Chem. 2013;288(15):10849–10859.
   PubMed Web of Science ®Google Scholar
• Alaiti MA, Ishikawa M, Masuda H, et al. Up-regulation of miR-210 by vascular endothelial growth factor in ex vivo expanded CD34+ cells enhances cell-mediated angiogenesis. J Cell Mol Med. 2012;16(10):2413–2421.
   PubMed Web of Science ®Google Scholar
• Xiao F, Qiu H, Zhou L, et al. WSS25 inhibits Dicer, downregulating microRNA-210, which targets Ephrin-A3, to suppress human microvascular endothelial cell (HMEC-1) tube formation. Glycobiology. 2013;23(5):524–535.
   PubMed Web of Science ®Google Scholar
• Bindra RS, Crosby ME, Glazer PM. Regulation of DNA repair in hypoxic cancer cells. Cancer Metastasis Rev. 2007;26(2):249–260.
   PubMed Web of Science ®Google Scholar
• Crosby ME, Kulshreshtha R, Ivan M, et al. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res. 2009;69(3):1221–1229.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4(3):321–327.
   PubMed Web of Science ®Google Scholar
• Wang H, Flach H, Onizawa M, et al. Negative regulation of Hif1a expression and TH17 differentiation by the hypoxia-regulated microRNA miR-210. Nat Immunol. 2014;15(4):393–401.
   PubMed Web of Science ®Google Scholar
• Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8(7):523–532.
   PubMed Web of Science ®Google Scholar
• Fayyad-Kazan H, Rouas R, Fayyad-Kazan M, et al. MicroRNA profile of circulating CD4-positive regulatory T cells in human adults and impact of differentially expressed microRNAs on expression of two genes essential to their function. J Biol Chem. 2012;287(13):9910–9922.
   PubMed Web of Science ®Google Scholar
• Zhao M, Wang LT, Liang GP, et al. Up-regulation of microRNA-210 induces immune dysfunction via targeting FOXP3 in CD4(+) T cells of psoriasis vulgaris. Clin Immunol. 2014;150(1):22–30.
   PubMed Web of Science ®Google Scholar
• Qi J, Qiao Y, Wang P, et al. microRNA-210 negatively regulates LPS-induced production of proinflammatory cytokines by targeting NF-kappaB1 in murine macrophages. FEBS Lett. 2012;586(8):1201–1207.
   PubMed Web of Science ®Google Scholar
• Moore LM, Zhang W. Targeting miR-21 in glioma: a small RNA with big potential. Expert Opin Ther Targets. 2010;14(11):1247–1257.
   PubMed Web of Science ®Google Scholar
• Bostjancic E, Zidar N, Glavac D. MicroRNA microarray expression profiling in human myocardial infarction. Dis Markers. 2009;27(6):255–268.
   PubMed Web of Science ®Google Scholar
• Thum T, Galuppo P, Wolf C, et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation. 2007;116(3):258–267.
   PubMed Web of Science ®Google Scholar
• Li T, Cao H, Zhuang J, et al. Identification of miR-130a, miR-27b and miR-210 as serum biomarkers for atherosclerosis obliterans. Clin Chim Acta. 2011;412(1–2):66–70.
   PubMed Web of Science ®Google Scholar
• Zeng L, Liu J, Wang Y, et al. MicroRNA-210 as a novel blood biomarker in acute cerebral ischemia. Front Biosci (Elite Ed). 2011;3:1265–1272.
   PubMedGoogle Scholar
• Lou YL, Guo F, Liu F, et al. miR-210 activates notch signaling pathway in angiogenesis induced by cerebral ischemia. Mol Cell Biochem. 2012;370(1–2):45–51.
   PubMed Web of Science ®Google Scholar
• White K, Lu Y, Annis S, et al. Genetic and hypoxic alterations of the microRNA-210-ISCU1/2 axis promote iron-sulfur deficiency and pulmonary hypertension. EMBO Mol Med. 2015;7(6):695–713.
   PubMed Web of Science ®Google Scholar
• Mathew LK, Simon MC. mir-210: a sensor for hypoxic stress during tumorigenesis. Mol Cell. 2009;35(6):737–738.
   PubMed Web of Science ®Google Scholar
• Cheng CJ, Bahal R, Babar IA, et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature. 2015;518(7537):107–110.
   PubMed Web of Science ®Google Scholar
• Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141(5):672–675.
   PubMed Web of Science ®Google Scholar
• Ying Q, Liang L, Guo W, et al. Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Hepatology. 2011;54(6):2064–2075.
   PubMed Web of Science ®Google Scholar
• Taddei ML, Cavallini L, Comito G, et al. Senescent stroma promotes prostate cancer progression: the role of miR-210. Mol Oncol. 2014;8(8):1729–1746.
   PubMed Web of Science ®Google Scholar
• Gee HE, Camps C, Buffa FM, et al. hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer. 2010;116(9):2148–2158.
   PubMed Web of Science ®Google Scholar
• Rivera-Diaz M, Miranda-Roman MA, Soto D, et al. MicroRNA-27a distinguishes glioblastoma multiforme from diffuse and anaplastic astrocytomas and has prognostic value. Am J Cancer Res. 2015;5(1):201–218.
   PubMed Web of Science ®Google Scholar
• Eilertsen M, Andersen S, Al-Saad S, et al. Positive prognostic impact of miR-210 in non-small cell lung cancer. Lung Cancer. 2014;83(2):272–278.
   PubMed Web of Science ®Google Scholar
• Jung EJ, Santarpia L, Kim J, et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer. 2012;118(10):2603–2614.
   PubMed Web of Science ®Google Scholar
• Rotkrua P, Shimada S, Mogushi K, et al. Circulating microRNAs as biomarkers for early detection of diffuse-type gastric cancer using a mouse model. Br J Cancer. 2013;108(4):932–940.
   PubMed Web of Science ®Google Scholar
• Ho AS, Huang X, Cao H, et al. Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol. 2010;3(2):109–113.
   PubMed Web of Science ®Google Scholar
• Wang J, Chen J, Chang P, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila). 2009;2(9):807–813.
   PubMed Web of Science ®Google Scholar
• Qu A, Du L, Yang Y, et al. Hypoxia-inducible miR-210 is an independent prognostic factor and contributes to metastasis in colorectal cancer. PLoS One. 2014;9(3):e90952.
   PubMed Web of Science ®Google Scholar
• Zhao A, Li G, Peoc’h M, et al. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol. 2013;94(1):115–120.
   PubMed Web of Science ®Google Scholar
• Eissa S, Matboli M, Hegazy MG, et al. Evaluation of urinary microRNA panel in bladder cancer diagnosis: relation to bilharziasis. Transl Res. 2015;165(6):731–739.
   PubMed Web of Science ®Google Scholar
• Quero L, Dubois L, Lieuwes NG, et al. miR-210 as a marker of chronic hypoxia, but not a therapeutic target in prostate cancer. Radiother Oncol. 2011;101(1):203–208.
   PubMed Web of Science ®Google Scholar
• Bao B, Ahmad A, Kong D, et al. Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. PLoS One. 2012;7(8):e43726.
   PubMed Web of Science ®Google Scholar
• Mei Y, Gao C, Wang K, et al. Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia. Cancer Sci. 2014;105(4):463–472.
   PubMed Web of Science ®Google Scholar
• Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105(30):10513–10518.
   PubMed Web of Science ®Google Scholar
• Song JH, Meltzer SJ. MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology. 2012;143(1):35–47e2.
   PubMed Web of Science ®Google Scholar
• Mi S, Lu J, Sun M, et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci USA. 2007;104(50):19971–19976.
   PubMed Web of Science ®Google Scholar
• Shen J, Liu Z, Todd NW, et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer. 2011;11:374.
   PubMed Web of Science ®Google Scholar
• Cai H, Lin L, Cai H, et al. Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma. Med Oncol. 2013;30(2):499.
   PubMed Web of Science ®Google Scholar
• Qiu S, Lin S, Hu D, et al. Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. J Transl Med. 2013;11:10.
   PubMed Web of Science ®Google Scholar
• Greither T, Wurl P, Grochola L, et al. Expression of microRNA 210 associates with poor survival and age of tumor onset of soft-tissue sarcoma patients. Int J Cancer. 2012;130(5):1230–1235.
   PubMed Web of Science ®Google Scholar
• Yang B, Liu B, Bi P, et al. An integrated analysis of differential miRNA and mRNA expressions in human gallstones. Mol Biosyst. 2015;11(4):1004–1011.
   PubMed Web of Science ®Google Scholar
• Hamama S, Noman MZ, Gervaz P, et al. MiR-210: a potential therapeutic target against radiation-induced enteropathy. Radiother Oncol. 2014;111(2):219–221.
   PubMed Web of Science ®Google Scholar
• Lorenzen JM, Kielstein JT, Hafer C, et al. Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol. 2011;6(7):1540–1546.
   PubMed Web of Science ®Google Scholar
• Lemaire J, Mkannez G, Guerfali FZ, et al. MicroRNA expression profile in human macrophages in response to Leishmania major infection. PLoS Negl Trop Dis. 2013;7(10):e2478.
   PubMed Web of Science ®Google Scholar
• Perri R, Nares S, Zhang S, et al. MicroRNA modulation in obesity and periodontitis. J Dent Res. 2012;91(1):33–38.
   PubMed Web of Science ®Google Scholar
• Stoecklin-Wasmer C, Guarnieri P, Celenti R, et al. MicroRNAs and their target genes in gingival tissues. J Dent Res. 2012;91(10):934–940.
   PubMed Web of Science ®Google Scholar
• Xu P, Zhao Y, Liu M, et al. Variations of microRNAs in human placentas and plasma from preeclamptic pregnancy. Hypertension. 2014;63(6):1276–1284.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Fei M, Xue G, et al. Elevated levels of hypoxia-inducible microRNA-210 in pre-eclampsia: new insights into molecular mechanisms for the disease. J Cell Mol Med. 2012;16(2):249–259.
   PubMed Web of Science ®Google Scholar
• Luo R, Shao X, Xu P, et al. MicroRNA-210 contributes to preeclampsia by downregulating potassium channel modulatory factor 1. Hypertension. 2014;64(4):839–845.
   PubMed Web of Science ®Google Scholar
• Kosaka N, Sugiura K, Yamamoto Y, et al. Identification of erythropoietin-induced microRNAs in haematopoietic cells during erythroid differentiation. Br J Haematol. 2008;142(2):293–300.
   PubMed Web of Science ®Google Scholar
• Bianchi N, Zuccato C, Lampronti I, et al. Expression of miR-210 during erythroid differentiation and induction of gamma-globin gene expression. BMB Rep. 2009;42(8):493–499.
   PubMed Web of Science ®Google Scholar
• Sarakul O, Vattanaviboon P, Tanaka Y, et al. Enhanced erythroid cell differentiation in hypoxic condition is in part contributed by miR-210. Blood Cells Mol Dis. 2013;51(2):98–103.
   PubMed Web of Science ®Google Scholar
• Yang GH, Wang F, Yu J, et al. MicroRNAs are involved in erythroid differentiation control. J Cell Biochem. 2009;107(3):548–556.
   PubMed Web of Science ®Google Scholar
• Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature. 2005;438(7068):685–689.
   PubMed Web of Science ®Google Scholar
• Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature. 2008;452(7189):896–899.
   PubMed Web of Science ®Google Scholar
• Babar IA, Cheng CJ, Booth CJ, et al. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci USA. 2012;109(26):E1695–E1704.
   PubMed Web of Science ®Google Scholar
• Yang W, Wei J, Guo T, et al. Knockdown of miR-210 decreases hypoxic glioma stem cells stemness and radioresistance. Exp Cell Res. 2014;326(1):22–35.
   PubMed Web of Science ®Google Scholar
• Fasanaro P, Greco S, Lorenzi M, et al. An integrated approach for experimental target identification of hypoxia-induced miR-210. J Biol Chem. 2009;284(50):35134–35143.
   PubMed Web of Science ®Google Scholar
• Shoji T, Nakasa T, Yamasaki K, et al. The effect of intra-articular injection of microRNA-210 on ligament healing in a rat model. Am J Sports Med. 2012;40(11):2470–2478.
   PubMed Web of Science ®Google Scholar
• Kawanishi Y, Nakasa T, Shoji T, et al. Intra-articular injection of synthetic microRNA-210 accelerates avascular meniscal healing in rat medial meniscal injured model. Arthritis Res Ther. 2014;16(6):488.
   PubMed Web of Science ®Google Scholar
• Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 2012;4(3):143–159.
   PubMed Web of Science ®Google Scholar
• Lee D, Sun S, Zhang XQ, et al. MicroRNA-210 and endoplasmic reticulum chaperones in the regulation of chemoresistance in glioblastoma. J Cancer. 2015;6(3):227–232.
   PubMed Web of Science ®Google Scholar
• Lu J, Xie F, Geng L, et al. Potential role of MicroRNA-210 as biomarker in human cancers detection: a meta-analysis. Biomed Res Int. 2015;2015:303987.
   PubMed Web of Science ®Google Scholar
• Hong L, Han Y, Zhang H, et al. miR-210: a therapeutic target in cancer. Expert Opin Ther Targets. 2013;17(1):21–28.
   PubMed Web of Science ®Google Scholar
• Hamilton MP, Rajapakshe K, Hartig SM, et al. Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif. Nat Commun. 2013;4:2730.
   PubMed Web of Science ®Google Scholar
• Rohwer N, Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat. 2011;14(3):191–201.
   PubMed Web of Science ®Google Scholar
• Hong L, Han Y, Zhang Y, et al. MicroRNA-21: a therapeutic target for reversing drug resistance in cancer. Expert Opin Ther Targets. 2013;17(9):1073–1080.
   PubMed Web of Science ®Google Scholar